Abstracts tagged "Inflammation"

Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Christopher Oliveira¹, Yenealem Temesgen-Oyelakin², Mohammad Naqi³, Nidhi Patel², Philip Parel², Massimo Gadina⁴, Stefania Dell'Orso², Stephen Brooks², Sarthak Gupta⁵, Nehal Mehta⁶, Sarfaraz Hasni³ and Mariana Kaplan³, ¹National Institutes of Health (NIH), Vienna, VA, ²National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…
Abstract Number: 1126 • ACR Convergence 2021
Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
Holly Philpott¹, Trevor Birmingham², Nicole Aye², Benoit Fiset³, Logan Walsh³, Brent Lanting² and Tom Appleton², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Obesity is a major risk factor for poor outcomes in knee osteoarthritis (OA) and may involve both mechanical and physiological stresses on joint tissues.…
Abstract Number: 1578 • ACR Convergence 2021
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
MARIANO ANDRES¹, Leticia Mendieta², Elena Argente-delcastillo¹, Miguel Trigueros³ and Alberto Miñano³, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Universidad Miguel Hernández, San Juan de Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante
Background/Purpose: Both hyperuricemia and monosodium urate crystals induce persistent inflammation. In vitro, soluble urate can prime innate immune cells and promote NLRP3 inflammasome activation and…
Abstract Number: 0274 • ACR Convergence 2021
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
juan Carlos Quevedo¹, Laura de Armás-Rillo², Antonia de Vera-González³, Laura Cáceres¹, Cristina Almeida¹, Alejandra González-Delgado³ and Iván Ferraz-Amaro³, ¹Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ²Universidad Europea de Canarias, Santa Cruz De Tenerife, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile.…
Abstract Number: 0916 • ACR Convergence 2021
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Lianne Gensler¹, Xenofon Baraliakos², Lars Bauer³, Bengt Hoepken³, Thomas Kumke³, Mindy Kim⁴ and Robert Landewé⁵, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: C-OPTIMISE was a phase 3b study investigating certolizumab pegol (CZP) maintenance dose continuation, reduction or withdrawal following achievement of sustained remission in patients with…
Abstract Number: 1196 • ACR Convergence 2021
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
Doortje Krijbolder¹, Fenne Wouters¹, Elise van Mulligen² and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…
Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Herman Tam¹, Alison Lopez², Mona Patel², Jonathan Rayment³, Lori Tucker⁴ and Catherine Biggs⁵, ¹Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, ³British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵[email protected], Vancouver, BC, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…
Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: 0073 • ACR Convergence 2020
A Cross-Species Map of Neutrophil Inflammatory Responses
Felix Radtke¹, Frank Huang², Peter Nigrovic³ and Ricardo Grieshaber-Bouyer⁴, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Baden-Wurttemberg, Germany, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Darmstadt, Baden-Wurttemberg, Germany, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany
Background/Purpose: Neutrophils are important mediators of immune defense as well as key protagonists in immune-mediated disease. How these cells adapt differently to sterile and septic…
Abstract Number: 0528 • ACR Convergence 2020
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies
Giorgia Grosso¹, Kerstin Sandholm², Aleksandra Antovic¹, Iva Gunnarsson¹, Agneta Zickert¹, Anna Vikerfors³, Lennart Truedsson⁴, Maria Bruzelius¹, Bo Nilsson⁵, Kristina Nilsson Ekdahl⁵ and Elisabet Svenungsson¹, ¹Karolinska University Hospital, Stockholm, Sweden, ²Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden, ³Swedish Medical Products Agency, Uppsala, Sweden, ⁴Lunds University, Lund, Sweden, ⁵Uppsala University, Uppsala, Sweden
Background/Purpose: C4b Binding Protein (C4BP) is the main inhibitor of the classical complement pathway. Both β2glycoprotein-I (β2GPI), the main antigen in the antiphospholipid syndrome (APS),…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 1041 • ACR Convergence 2020
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center
Sanjeev Patil¹, Justine Cheng², Lorraine Provencher³ and Scott Vogelgesang⁴, ¹University of Vermont Medical Center, Essex Junction, VT, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…
Abstract Number: 1400 • ACR Convergence 2020
cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis
Sigrun Hofmann¹, Franz Kapplusch², Susanne Abraham³, Sarah Northey², Susanne Russ¹, Felix Schulze¹, Anna Surace⁴ and Christian Hedrich⁵, ¹Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ²Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Liverpool, United Kingdom, ³Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ⁴Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, Liverpool, United Kingdom, ⁵University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Psoriasis is a systemic autoimmune/inflammatory condition that primarily affects the skin, but also other organ systems. Effector CD4+ T lymphocytes have been identified as…
Abstract Number: 1796 • ACR Convergence 2020
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
Jennifer Davies¹, Emil Carlsson¹, Angela Midgley¹, Eve Smith¹, Ian Bruce², Michael Beresford¹ and Christian Hedrich³, ¹Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, ²Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].